Study of a Tankyrase Inhibitor RK-582 for Patients With Unresectable Metastatic Colorectal Cancer
NCT06853496
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
48
Enrollment
OTHER
Sponsor class
Conditions
Unresectable Colorectal Neoplasm Metastasis
Interventions
DRUG:
RK-582
Sponsor
Eiji Shinozaki
Collaborators
[object Object]